Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00110435 | A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077) | PHASE3 | COMPLETED | 1,229 | — | — | May 1, 2005 | Dec 1, 2005 | Aug 15, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0653A, ezetimibe (+) simvastatin | DRUG | - |
| Duration of Treatment: 4 wk placebo run in then 6 wk active | DRUG | - |
| Comparator: atorvastatin | DRUG | - |
Inclusion Criteria: * Men and women aged 18 to 79 years who have a confirmed diagnosis of type 2 diabetes mellitus with elevated cholesterol levels may be eligible to participate in a study to assess the efficacy and safety of the two marketed drugs. Exclusion Criteria: * Type 1 Diabetes Mellitus...